A Phase I/II Trial of Gefitinib Given Concurrently With Radiotherapy in Patients With Nonmetastatic Prostate Cancer

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone et al. · Journal of Clinical Oncology · 2003 · 2.9K citations

Medicine, Oncology, Pharmacology +13

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference

Mack Roach, Gerald E. Hanks, Howard D. Thames et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 2.7K citations

Medicine, Radiation Oncology, Urology +14

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Vera Hirsh, Tony Mok et al. · The Lancet · 2008 · 1.2K citations

Medicine, Oncology, Pharmacology +8

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry et al. · Journal of Clinical Oncology · 2002 · 763 citations

Medicine, Oncology, Pharmacology +14

Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.

Jennifer R. Grandis, Stephanie D. Drenning, Anutosh Chakraborty et al. · Journal of Clinical Investigation · 1998 · 508 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +13